与年龄相关的神经退行性疾病中蛋白质后翻译性修改的景观:蛋白质聚合,改变细胞过程和治疗学的影响
Akash Kumar Singh1, Tapas K Kundu1
1Transcription and Disease Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bengaluru 560 064, India.
ACS omega
|March 9, 2026
概括
老化神经元中的蛋白质聚合与神经退行性疾病有关. 用小分子准翻译后修改 (PTM) 为阿尔茨海默氏症和帕金森病等疾病提供了治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 蛋白质聚合是神经退行性疾病的标志.
- 蛋白质质量控制,包括翻译后修改 (PTM) 和降解系统,对于神经元功能至关重要.
- 功能失调的蛋白质质量控制与阿尔茨海默病,帕金森病和亨廷顿病有关.
研究的目的:
- 审查PTMs在神经退行性疾病中蛋白质聚合中的作用.
- 突出针对PTM及其修饰酶的治疗策略.
主要方法:
- 对PTM和神经退行症研究的文献综述.
- 对向PTM通路的小分子调节器的分析.
主要成果:
- 改变的PTM有助于非功能性蛋白质的积累.
- 小分子激活剂/PTM抑制剂在恢复神经元功能方面表现有前途.
- 向修饰酶是一种可行的治疗途径.
结论:
- 在衰老的神经元中,PTMs极大地影响蛋白质稳态.
- 调节PTM为神经退行性疾病提供了一个有前途的治疗策略.
- 对小分子调制器的进一步研究是有必要的.
相关概念视频
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Neural Regulation
43.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.9K
Amyloid Fibrils
12.4K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
12.4K
Protein Modifications in the RER
7.3K
Modification of secretory and transmembrane proteins entering the rough ER begins in the ER lumen. These modifications aid in protein folding and stabilize the acquired tertiary structure. Protein modifications in the rough ER co-occur at different stages of protein folding.
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal...
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal...
7.3K
Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K


